Overview

  • Product nameAnti-Apolipoprotein A I antibody (HRP)See all Apolipoprotein A I primary antibodies ...
  • Description
    Goat polyclonal to Apolipoprotein A I (HRP)
  • ConjugationHRP
  • SpecificitySpecific binding to Apo A-I. No cross-reaction with Apo AII, Apo B-100, Apo CI, Apo CII, Apo CIII, and Apo E.
  • Tested applicationsELISA, WBmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Full length native protein (purified) (Human).

Applications

Our Abpromise guarantee covers the use of ab20784 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA
WB
  • Application notesELISA: 1/4000 - 1/32000. WB: 1/4000 - 1/32000. Predicted molecular weight: 31 kDa. Dilution optimised using Chromogenic detection. Can be used to detect the existence of Apo AI in plasma and lipoproteins. Not yet tested in other applications. Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionParticipates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, activates spermatozoa motility.
    • Tissue specificityMajor protein of plasma HDL, also found in chylomicrons. Synthesized in the liver and small intestine.
    • Involvement in diseaseDefects in APOA1 are a cause of high density lipoprotein deficiency type 2 (HDLD2) [MIM:604091]; also known as familial hypoalphalipoproteinemia (FHA). Inheritance is autosomal dominant.
      Defects in APOA1 are a cause of the low HDL levels observed in high density lipoprotein deficiency type 1 (HDLD1) [MIM:205400]; also known as analphalipoproteinemia or Tangier disease (TGD). HDLD1 is a recessive disorder characterized by the absence of plasma HDL, accumulation of cholesteryl esters, premature coronary artery disease, hepatosplenomegaly, recurrent peripheral neuropathy and progressive muscle wasting and weakness. In HDLD1 patients, ApoA-I fails to associate with HDL probably because of the faulty conversion of pro-ApoA-I molecules into mature chains, either due to a defect in the converting enzyme activity or a specific structural defect in Tangier ApoA-I.
      Defects in APOA1 are the cause of amyloid polyneuropathy-nephropathy Iowa type (AMYLIOWA) [MIM:107680]; also known as amyloidosis van Allen type or familial amyloid polyneuropathy type III. AMYLIOWA is a hereditary generalized amyloidosis due to deposition of amyloid mainly constituted by apolipoprotein A1. The clinical picture is dominated by neuropathy in the early stages of the disease and nephropathy late in the course. Death is due in most cases to renal amyloidosis. Severe peptic ulcer disease can occurr in some and hearing loss is frequent. Cataracts is present in several, but vitreous opacities are not observed.
      Defects in APOA1 are a cause of amyloidosis type 8 (AMYL8) [MIM:105200]; also known as systemic non-neuropathic amyloidosis or Ostertag-type amyloidosis. AMYL8 is a hereditary generalized amyloidosis due to deposition of apolipoprotein A1, fibrinogen and lysozyme amyloids. Viscera are particularly affected. There is no involvement of the nervous system. Clinical features include renal amyloidosis resulting in nephrotic syndrome, arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin rash.
    • Sequence similaritiesBelongs to the apolipoprotein A1/A4/E family.
    • Post-translational
      modifications
      Palmitoylated.
      Phosphorylation sites are present in the extracelllular medium.
    • Cellular localizationSecreted.
    • Information by UniProt
    • Database links
    • Alternative names
      • Apo AI antibody
      • Apo-AI antibody
      • ApoA I antibody
      • ApoA-I antibody
      • APOA1 antibody
      • APOA1/APOC3 fusion gene antibody
      • APOA1_HUMAN antibody
      • Apolipoprotein A I precursor antibody
      • Apolipoprotein A-I(1-242) antibody
      • Apolipoprotein A1 antibody
      • Apolipoprotein AI antibody
      • Apolipoprotein of high density lipoprotein antibody
      • ApolipoproteinAI antibody
      • Brp14 antibody
      • Ltw1 antibody
      • Lvtw1 antibody
      • MGC117399 antibody
      • Sep1 antibody
      • Sep2 antibody
      see all

    References for Anti-Apolipoprotein A I antibody (HRP) (ab20784)

    This product has been referenced in:
    • Gugliucci A  et al. Small-dense low-density lipoproteins are the predominant apoB-100-containing lipoproteins in cord blood. Clin Biochem 47:475-7 (2014). WB ; Human . Read more (PubMed: 24362269) »
    • Park KH  et al. Senescence-related truncation and multimerization of apolipoprotein A-I in high-density lipoprotein with an elevated level of advanced glycated end products and cholesteryl ester transfer activity. J Gerontol A Biol Sci Med Sci 65:600-10 (2010). Sandwich ELISA . Read more (PubMed: 20421239) »

    See all 2 Publications for this product

    Product Wall

    Abcam guarantees this product to work in the species/application used in this Abreview.
    Application ELISA
    Sample Human Recombinant protein (human recombinant protein were used)
    Specification human recombinant protein were used
    Blocking step BSA as blocking agent for 2 hour(s) and 0 minute(s) · Concentration: 1% · Temperature: 25°C
    Type Direct
    Username

    Abcam user community

    Verified customer

    Submitted Mar 12 2008

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"